Where each one stands
A plain-English scoreboard of where each peptide sits in the U.S. compounding review - what the FDA is evaluating, and what still has to happen before anything changes. Every status links to a primary source. We update this as the review moves.
Legend
Panel recommended for the 503A list (July 23-24, 2026; advisory, non-binding)
Panel declined to recommend
Cannot be lawfully compounded today
On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed these seven substances for possible inclusion on the 503A bulk-drug-substances list, the list that determines whether a licensed pharmacy may legally compound them. The committee recommended six of the seven (all except DSIP/Emideltide), over the objection of FDA staff, who had recommended adding none. The "use evaluated" column is the specific use the FDA scientifically reviewed for each, per the agency's official meeting page. The committee's vote is advisory and non-binding.
| Peptide | Status | Use FDA evaluated | Primary source |
|---|---|---|---|
| BPC-157 | Recommended (advisory) | Ulcerative colitis | FDA briefing doc (PDF) |
| KPV | Recommended (advisory) | Wound healing & inflammatory conditions | FDA briefing doc (PDF) |
| TB-500 | Recommended (advisory) | Wound healing | FDA briefing doc (PDF) |
| MOTS-c | Recommended (advisory) | Obesity and osteoporosis | FDA briefing doc (PDF) |
| DSIP (FDA name: Emideltide) | Not recommended | Opioid withdrawal, chronic insomnia, narcolepsy | FDA briefing doc (PDF) |
| Semax | Recommended (advisory) | Cerebral ischemia, migraine, trigeminal neuralgia | FDA briefing doc (PDF) |
| Epitalon | Recommended (advisory) | Insomnia | FDA briefing doc (PDF) |
Source: FDA, Meeting of the Pharmacy Compounding Advisory Committee, July 23-24, 2026, including the linked FDA briefing documents. "DSIP" (delta sleep-inducing peptide) is the common name; the FDA lists it as "Emideltide."
A patented, investigational GLP-1-class drug still in clinical trials. The FDA has stated that drugs like retatrutide cannot be lawfully compounded. It is not part of the peptide-compounding review above.
Source: FDA, FDA's Concerns with Unapproved GLP-1 Drugs.
A "tanning" peptide never approved by the FDA and the subject of consumer-safety warnings here and abroad. It was placed in the FDA's "Category 2" in 2023 and removed in April 2026; it is not on the July 23-24 agenda, but is among the peptides expected to be taken up in a later FDA review round. No legal compounding pathway exists for it today. See our Melanotan II profile and the international warnings.
See International Comparison for TGA / MHRA enforcement.
Several other peptides in our library - GHK-Cu, LL-37, PEG-MGF, DiHexa - are not FDA-approved and are not on the July 2026 agenda. Their compounding status is unchanged by this particular review.
The advisory vote is a recommendation - not the decision. Real access changes only if the FDA later opens a formal rulemaking with a public comment window, the stage where an ordinary person's comment carries legal weight. Most people never hear that window opened. See how the process works →
Peppies is an independent private venture and is not affiliated with the FDA. This tracker is educational; verify each status against the linked primary source.
Get notified
The vote is advisory. The decision that shapes access comes later - if and when the FDA opens a formal public comment window. Most people never hear it opened. Join the list and we'll tell you the instant it does, with step-by-step instructions to file a comment that counts.
